Condition: Covid19 · SARS-CoV Infection · Transplantation Infection · Sponsor: Universitaire Ziekenhuizen KU Leuven
This project will provide novel data using a large cohort of more than 3000 transplanted patients. Risk and protective factors for SARS-CoV-2 infection and COVID-19 disease severity will be identified. The proportion of patients who develop antibodies after infection will be revealed. In this way the presence of these antibodies can be evaluated as a test for prior infection. Our study additionally will demonstrate how long these antibodies remain present and whether they are protective against a new infection.
This description comes directly from the study's public registry record.
Jef Verbeek, MD, PhD · + 32 16 34 42 25 · jef.verbeek@uzleuven.be
Natalie Van den Ende · +32 16 340749 · natalie.vandenende@uzleuven.be
Always discuss trial participation with your own doctor first.
| UZ Leuven | Leuven, Vlaams Brabant, Belgium | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04579471